DnB Asset Management
WST icon

DnB Asset Management’s West Pharmaceutical WST Stock Holding History

DnB Asset Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.73M Buy
15,960
+1,132
+8% +$346K 0.02% 461
2026
Q1 		$3.72M Buy
14,828
+381
+3% +$94.8K 0.01% 499
2025
Q4 		$3.97M Buy
14,447
+975
+7% +$267K 0.01% 493
2025
Q3 		$3.53M Buy
13,472
+705
+6% +$171K 0.01% 498
2025
Q2 		$2.79M Hold
12,767
– – 0.01% 509
2025
Q1 		$2.86M Sell
12,767
-25
-0.2% -$6.89K 0.01% 500
2024
Q4 		$4.19M Buy
12,792
+332
+3% +$104K 0.02% 416
2024
Q3 		$3.74M Buy
12,460
+809
+7% +$248K 0.02% 438
2024
Q2 		$3.84M Buy
11,651
+590
+5% +$209K 0.02% 397
2024
Q1 		$4.38M Sell
11,061
-3,958
-26% -$1.46M 0.02% 375
2023
Q4 		$5.29M Sell
15,019
-203
-1% -$71.8K 0.03% 351
2023
Q3 		$5.71M Buy
15,222
+247
+2% +$95.5K 0.03% 325
2023
Q2 		$5.73M Buy
14,975
+18
+0.1% +$6.43K 0.03% 332
2023
Q1 		$5.18M Buy
14,957
+515
+4% +$150K 0.03% 355
2022
Q4 		$3.4M Sell
14,442
-67
-0.5% -$15.9K 0.02% 418
2022
Q3 		$3.57M Sell
14,509
-433
-3% -$132K 0.03% 398
2022
Q2 		$4.52M Buy
14,942
+443
+3% +$144K 0.03% 357
2022
Q1 		$5.95M Buy
14,499
+1,417
+11% +$555K 0.04% 335
2021
Q4 		$6.14M Sell
13,082
-263
-2% -$113K 0.04% 329
2021
Q3 		$5.67M Buy
13,345
+162
+1% +$68.3K 0.04% 328
2021
Q2 		$4.73M Buy
13,183
+1,236
+10% +$408K 0.03% 380
2021
Q1 		$3.37M Buy
11,947
+850
+8% +$243K 0.02% 421
2020
Q4 		$3.14M Buy
11,097
+219
+2% +$61.5K 0.03% 362
2020
Q3 		$2.99M Buy
+10,878
New +$2.88M 0.03% 317
2020
Q2 		– Sell
-11,074
Closed -$1.69M – 627
2020
Q1 		$1.69M Sell
11,074
-1,263
-10% -$194K 0.02% 378
2019
Q4 		$1.85M Buy
+12,337
New +$1.8M 0.02% 472

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

DnB Asset Management's WST Position: Q2 2026 in Review

DnB Asset Management increased its West Pharmaceutical (WST) stake by 7.6% in Q2 2026, buying an estimated $346K and bringing the position to 15,960 shares worth $5.73M. The position accounts for 0.02% of the portfolio, ranked #461.

DnB Asset Management first reported a position in WST in Q4 2019 and has held it in 26 quarters since. The position peaked at $6.14M in Q4 2021. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • DnB Asset Management held 15,960 shares of West Pharmaceutical worth $5.73M as of Q2 2026.
  • DnB Asset Management bought 1,132 West Pharmaceutical shares in Q2 2026, an estimated $346K.
  • West Pharmaceutical made up 0.02% of DnB Asset Management's portfolio in Q2 2026, its #461 holding.
  • DnB Asset Management first reported a position in West Pharmaceutical in Q4 2019 and has held it in 26 quarters since.
  • DnB Asset Management's West Pharmaceutical position peaked at $6.14M in Q4 2021.
  • 831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.